Analyses from a Phase 2 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with IgA Nephropathy: The PHOENIX Study: Presentation at ASN Kidney Week 2018

PHOENIX was a Phase 2, open-label, multi-center, US-only trial of bardoxolone methyl in four separate cohorts of patients with autosomal dominant polycystic kidney disease, IgA nephropathy, type 1 diabetic chronic kidney disease, or focal segmental glomerulosclerosis. The trial enrolled 26 patients with IgA nephropathy and the primary endpoint was change in estimated glomerular filtration rate at Week 12.